Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Luke Roy George Pike, M.D.

Profile Picture

Memorial University, CanadaB.Sc.05/2007Chemistry and Biochemistry
University of Oxford, EnglandD.Phil.07/2011Medical Oncology
Yale School of Medicine, ConnecticutM.D.5/2015Medicine
Massachusetts General Hospital, Massachusetts Internship7/2016Internal Medicine
Harvard Radiation Oncology Program, Massachusetts Residency6/2020Radiation Oncology
2007 - 2011
Rhodes Scholarship

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Pike LRG, Royce TJ, Mahal AR, Kim DW, Hwang WL, Mahal BA, Sanford NN. Outcomes of HPV-Associated Squamous Cell Carcinoma of the Head and Neck: Impact of Race and Socioeconomic Status. J Natl Compr Canc Netw. 2020 02; 18(2):177-184. PMID: 32023531.
  2. Sanford NN, Hwang WL, Pike LRG, Lam AC, Royce TJ, Mahal BA. Trimodality therapy for HPV-positive oropharyngeal cancer: A population-based study: Trimodality therapy for HPV+?OPC. Oral Oncol. 2019 11; 98:28-34. PMID: 31536843.
  3. Mahal AR, Butler S, Franco I, Muralidhar V, Larios D, Pike LRG, Zhao SG, Sanford NN, Dess RT, Feng FY, D'Amico AV, Spratt DE, Yu JB, Nguyen PL, Rebbeck TR, Mahal BA. Conservative management of low-risk prostate cancer among young versus older men in the United States: Trends and outcomes from a novel national database. Cancer. 2019 10 01; 125(19):3338-3346. PMID: 31251398.
  4. Pike LRG, D'Amico AV. Author Reply. Urology. 2019 04; 126:151. PMID: 30929689.
  5. Fareed MM, Pike LRG, Bang A, Huynh MA, Taylor A, Spektor A, Awad MM, Ott PA, Krishnan M, Balboni TA, Schoenfeld JD. Palliative Radiation Therapy for Vertebral Metastases and Metastatic Cord Compression in Patients Treated With Anti-PD-1 Therapy. Front Oncol. 2019; 9:199. PMID: 30984622.
  6. Pike LRG, McKenna MJ, Shih HA. With Regard to the Brainstem, Size Matters Most. Int J Radiat Oncol Biol Phys. 2019 03 15; 103(4):799-800. PMID: 30784526.
  7. Pike LRG, Wu J, Chen MH, Loffredo M, Renshaw AA, Pfail J, Kantoff PW, D'Amico AV. Time to Prostate-specific Antigen Nadir and the Risk of Death From Prostate Cancer Following Radiation and Androgen Deprivation Therapy. Urology. 2019 04; 126:145-151. PMID: 30664895.
    Citations:    Fields:    
  8. Pike LRG, Bang A, Mahal BA, Taylor A, Krishnan M, Spektor A, Cagney DN, Aizer AA, Alexander BM, Rahma O, Balboni T, Ott PA, Hodi FS, Schoenfeld JD. The Impact of Radiation Therapy on Lymphocyte Count and Survival in Metastatic Cancer Patients Receiving PD-1 Immune Checkpoint Inhibitors. Int J Radiat Oncol Biol Phys. 2019 01 01; 103(1):142-151. PMID: 30227198.
    Citations:    Fields:    
  9. Pike LRG, Hwang WL, Royce TJ, Sanford NN, Mahal BA. HPV status predicts for improved survival following chemotherapy in metastatic squamous cell carcinoma of the oropharynx. Oral Oncol. 2018 11; 86:69-74. PMID: 30409322.
    Citations:    Fields:    
  10. Sanford NN, Mahal BA, Royce TJ, Pike LRG, Hwang WL. Sex Disparity and Copy Number Alterations in Esophageal Squamous Cell Carcinoma. Clin Gastroenterol Hepatol. 2019 05; 17(6):1207-1209. PMID: 30120994.
    Citations:    Fields:    
  11. Hwang WL, Pike LRG, Royce TJ, Mahal BA, Loeffler JS. Safety of combining radiotherapy with immune-checkpoint inhibition. Nat Rev Clin Oncol. 2018 08; 15(8):477-494. PMID: 29872177.
    Citations: 1     Fields:    
  12. Pike LRG, Bang A, Ott P, Balboni T, Taylor A, Catalano P, Rawal B, Spektor A, Krishnan M, Cagney D, Alexander B, Aizer AA, Buchbinder E, Awad M, Gandhi L, Hodi FS, Schoenfeld JD. Radiation and PD-1 inhibition: Favorable outcomes after brain-directed radiation. Radiother Oncol. 2017 07; 124(1):98-103. PMID: 28662869.
    Citations: 4     Fields:    Translation:Humans
  13. Bang A, Wilhite TJ, Pike LRG, Cagney DN, Aizer AA, Taylor A, Spektor A, Krishnan M, Ott PA, Balboni TA, Hodi FS, Schoenfeld JD. Multicenter Evaluation of the Tolerability of Combined Treatment With PD-1 and CTLA-4 Immune Checkpoint Inhibitors and Palliative Radiation Therapy. Int J Radiat Oncol Biol Phys. 2017 06 01; 98(2):344-351. PMID: 28463153.
    Citations: 14     Fields:    Translation:Humans
  14. Stachelek GC, Peterson-Roth E, Liu Y, Fernandez RJ, Pike LR, Qian JM, Abriola L, Hoyer D, Hungerford W, Merkel J, Glazer PM. YU238259 Is a Novel Inhibitor of Homology-Dependent DNA Repair That Exhibits Synthetic Lethality and Radiosensitization in Repair-Deficient Tumors. Mol Cancer Res. 2015 Oct; 13(10):1389-97. PMID: 26116172.
    Citations: 1     Fields:    Translation:HumansAnimalsCells
  15. Pike LR, Singleton DC, Buffa F, Abramczyk O, Phadwal K, Li JL, Simon AK, Murray JT, Harris AL. Transcriptional up-regulation of ULK1 by ATF4 contributes to cancer cell survival. Biochem J. 2013 Jan 15; 449(2):389-400. PMID: 23078367.
    Citations: 46     Fields:    Translation:HumansAnimalsCells
  16. Pike LR, Phadwal K, Simon AK, Harris AL. ATF4 orchestrates a program of BH3-only protein expression in severe hypoxia. Mol Biol Rep. 2012 Dec; 39(12):10811-22. PMID: 23090478.
    Citations: 5     Fields:    Translation:HumansCells
  17. Phadwal K, Alegre-Abarrategui J, Watson AS, Pike L, Anbalagan S, Hammond EM, Wade-Martins R, McMichael A, Klenerman P, Simon AK. A novel method for autophagy detection in primary cells: impaired levels of macroautophagy in immunosenescent T cells. Autophagy. 2012 Apr; 8(4):677-89. PMID: 22302009.
    Citations: 35     Fields:    Translation:HumansAnimalsCells
  18. Yang J, Jubb AM, Pike L, Buffa FM, Turley H, Baban D, Leek R, Gatter KC, Ragoussis J, Harris AL. The histone demethylase JMJD2B is regulated by estrogen receptor alpha and hypoxia, and is a key mediator of estrogen induced growth. Cancer Res. 2010 Aug 15; 70(16):6456-66. PMID: 20682797.
    Citations: 55     Fields:    Translation:HumansCells
  19. Milani M, Rzymski T, Mellor HR, Pike L, Bottini A, Generali D, Harris AL. The role of ATF4 stabilization and autophagy in resistance of breast cancer cells treated with Bortezomib. Cancer Res. 2009 May 15; 69(10):4415-23. PMID: 19417138.
    Citations: 103     Fields:    Translation:HumansCells
  20. Croke JM, Pike LR, MacPhee DJ. The focal adhesion protein Hic-5 is highly expressed in the rat myometrium during late pregnancy and labour and co-localizes with FAK. Reprod Biol Endocrinol. 2007 Jun 05; 5:22. PMID: 17550607.
    Citations: 3     Fields:    Translation:AnimalsCells
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact feedbackcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Pike's Networks
Click the
buttons for more information and interactive visualizations!
Concepts (144)
Co-Authors (26)
Similar People (60)
Same Department 
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.